Dr. Williams previously worked in the same capacity at Osiris Therapeutics, according to a news release. She is a fellow in the American Institute for Medical and Biological Engineering.
“Michelle has been a thought leader in regenerative medicine for two decades,” Randy Mills, PhD, CEO of Aziyo, said in the release. “She has a track record of consistently developing commercially successful products, including Osteocel, the world’s first stem cell product with cumulative sales of over $1 billion. We believe her ability to develop great products, backed by strong science and through efficient use of capital, will create significant value for Aziyo.”
